REGN vs RYM · P/E 14, rev $14.34B vs rev $9.7M
Regeneron Pharmaceuticals Inc (REGN) versus RYTHM, Inc. (RYM) — a side-by-side from cached financials, not a winner call.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
RYTHM, Inc. (RYM) is a tobacco company listed on NASDAQ.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Latest reported RYM revenue for 2024-12-31 was $9.7M. Net income was -$41.7M. Revenue was down 36.1% from 2023-12-31 to 2024-12-31. RYM currently screens at market cap $59.1M.
REGN currently screens at market cap $59.10B and trailing P/E 13.9. RYM currently screens at market cap $59.1M.
Not investment advice. Open the REGN and RYM stock pages for the full models.
Not investment advice.